Comprehensive pan‑cancer analysis reveals ubiquitin‑conjugating enzyme 2T as a potential biomarker for prognosis and cancer immunity

Ubiquitin-conjugating enzyme 2T (UBE2T) constitutes a critical component of the ubiquitin-proteasome system and is involved in tumorigenesis. The <i>UBE2T</i> gene has been extensively characterized. In the present study, comprehensive analyses using various databases and R-based tools revealed elevated <i>UBE2T</i> expression across multiple tumor types, where its upregulation was shown to be associated with poor clinical outcomes and prognosis. Gene variation analysis identified 'amplification' as the predominant alteration in the <i>UBE2T</i> gene, followed by mutations; data from the GSCALite database further demonstrated a high frequency of <i>UBE2T</i> copy number variations and relatively infrequent single nucleotide variants across pan-cancer cohorts. In addition, <i>UBE2T</i> expression showed a positive correlation with trametinib and selumetinib sensitivity, and a negative correlation with CD-437 and mitomycin. Moreover, <i>UBE2T</i> expression was shown to be significantly associated with tumor immune markers, checkpoint genes and immune cell infiltration. Functionally, elevated <i>UBE2T</i> expression was linked to changes in key cellular processes, including proliferation, invasion and epithelial-mesenchymal transition. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes analyses and Gene Set Enrichment Analysis implicated pathways such as 'cell cycle', 'ubiquitin-mediated proteolysis', 'p53 signaling' and 'mismatch repair' as key mechanisms through which <i>UBE2T</i> may exert oncogenic effects. Overall, <i>UBE2T</i> has emerged as a potentially valuable prognostic biomarker and therapeutic target in oncology.